Soft tablet containing high molecular weight polyethylene oxide
AssigneeMcNeil-PPC, Inc.
InventorsJoseph Luber, Frank J. Bunick
Life of this patent
Estimating the term…
Abstract
The invention relates to an immediate release tablet capable of being chewed or disintegrated in the oral cavity, which comprises a pharmaceutically active ingredient, and a matrix comprising polyethylene oxide having a weight average molecular weight of from about 500,000 to about 10,000,000. The tablet possesses exceptionally good mouthfeel and stability.
Claims13
An immediate release dosage form capable of being chewed or disintegrated in the oral cavity prior to swallowing, comprising:
- a. a pharmaceutically active ingredient;
- and
- b. a matrix comprising, based upon the total weight of the dosage form, from about 0.25 percent to about 5 percent of polyethylene oxide having a weight average molecular weight of from about 500,000 to about 10,000,000,
- wherein the active ingredient is selected from the group consisting of bisacodyl, famotadine, ranitidine, cimetidine, prucalopride, diphenoxylate, loperamide, lactase, mesalamine, bismuth, antacids, and pharmaceutically acceptable salts, esters, isomers, and mixtures therof.
An immediate release dosage form capable of being chewed or disintegrated in the oral cavity prior to swallowing, comprising:
- a. a pharmaceutically active ingredient;
- and
- b. a matrix comprising, based upon the total weight of the dosage form, from about 0.25 percent to about 5 percent of polyethylene oxide having a weight average molecular weight of from about 500,000 to about 10,000,000,
- wherein the active ingredient is selected from the group consisting of acetaminophen, acetyl salicylic acid, ibuprofen, naproxen, ketoprofen, flurbiprofen, diclofenac, cyclobenzaprine, meloxicam, rofecoxib, celecoxib, and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.
An immediate release dosage form capable of being chewed or disintegrated in the oral cavity prior to swallowing, comprising:
- a. a pharmaceutically active ingredient;
- and
- b. a matrix comprising, based upon the total weight of the dosage form, from about 0.25 percent to about 5 percent of polyethylene oxide having a weight average molecular weight of from about 500,000 to about 10,000,000,
- wherein the active ingredient is selected from the group consisting of pseudoephedrine, phenylpropanolamine, chlorpheniramine, dextromethorphan, diphenhydramine, astemizole, terfenadine, fexofenadine, loratadine, cetirizine, mixtures thereof and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.
An immediate release dosage form capable of being chewed or disintegrated in the oral cavity prior to swallowing, comprising:
- a. a pharmaceutically active ingredient;
- and
- b. a matrix comprising polyethylene oxide having a weight average molecular weight of from about 500,000 to about 10,000,000, wherein the dosage form contains, based upon the total weight of the dosage form, from about 0.25 percent to about 2.0 percent of polyethylene oxide.
An immediate release dosage form capable of being chewed or disintegrated in the oral cavity prior to swallowing, comprising:
- a. a pharmaceutically active ingredient;
- b. a matrix comprising, based upon the total weight of the dosage form, from about 0.25 percent to about 5.0 percent of polyethylene oxide having a weight average molecular weight of from about 500,000 to about 10,000,000;
- and
- c. an antioxidant.
Dependencies are inferred from the claim text.